Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Treating people in low-income countries for major depressive disorder can also help improve their physical health and household members' well-being, demonstrating that mental health treatments can ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Medically reviewed by Michael MacIntyre, MD Treatment-resistant depression (TRD) occurs when major depressive disorder (MDD) ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Treating people in low-income countries for major depressive disorder can also help improve their physical health and household members' wellbeing, demonstrating that mental health treatments can ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptomsSuicidal ideation decreased by 80%SPN-820 was ...

Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings ...